A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Public ClinicalTrials.gov record NCT05686239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with the tasks. Then, subjects will be given either RL-007 or a placebo for 6 weeks and then repeat the cognitive tasks. The researchers will compare the results at the end of the treatment period to the baseline to see if there have been any changes in performance. Additionally, several safety measures will be collected throughout the study (blood pressure, physical exam, ECGs, etc) to evaluate if there are any side effects from taking RL-007.
Study identification
- NCT ID
- NCT05686239
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 242 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2022 (Actual)
- Primary completion
- Apr 9, 2025 (Actual)
- Completion
- Apr 9, 2025 (Actual)
- Last update posted
- Jul 30, 2025
2022 – 2025
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Recognify Research Site | Culver City | California | 90230 | — |
| Collaborative Neuroscience Research | Garden Grove | California | 92845 | — |
| Recognify Research Site | Lafayette | California | 94549 | — |
| Recognify Research Site | Oceanside | California | 92056 | — |
| Recognify Research Site | Orange | California | 92868 | — |
| Recognify Research Site | Torrance | California | 90502 | — |
| Recognify Research Site | Hialeah | Florida | 33016 | — |
| Recognify Research Site | Miami | Florida | 33135 | — |
| Recognify Research Site | Miami Lakes | Florida | 33016 | — |
| Recognify Research Site | Atlanta | Georgia | 30030 | — |
| Recognify Research Site | Augusta | Georgia | 30912 | — |
| Recognify Research Site | Gaithersburg | Maryland | 20877 | — |
| Recognify Research Site | Berlin | New Jersey | 08009 | — |
| Recognify Research Site | Brooklyn | New York | 11235 | — |
| Recognify Research Site | Chapel Hill | North Carolina | 27599 | — |
| Recognify Research Site | Cincinnati | Ohio | 45219 | — |
| Recognify Research Site | Cleveland | Ohio | 44122 | — |
| Recognify Research Site | Dallas | Texas | 75231 | — |
| Recognify Research Site | Houston | Texas | 77074 | — |
| Recognify Research Site | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05686239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05686239 live on ClinicalTrials.gov.